Novartis Meningitis Vaccine Performing Well In Late-stage Trials
September 13, 2010 · Filed Under Meningitis · Comment
According to Bloomberg, Novartis AG (NVS) recently reported that phase III trials of their Meningitis B vaccine were meeting its goals. While many forms of the disease are preventable, this vaccine is aimed at treating infants, who are particularly susceptible, and to whom the disease is most lethal. Shares of NVS are up .41% on moderate volume.
-Michael B. Sauter
